1
|
Rallapalli S, Guhathakurta S, Korrapati PS. Isolation, growth kinetics, and immunophenotypic characterization of adult human cardiac progenitor cells. J Cell Physiol 2020; 236:1840-1853. [PMID: 33242343 DOI: 10.1002/jcp.29965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 07/10/2020] [Accepted: 07/13/2020] [Indexed: 11/10/2022]
Abstract
The discovery of cardiac progenitor cells (CPCs) has raised expectations for the development of cell-based therapy of the heart. Although cell therapy is emerging as a novel treatment for heart failure, several issues still exist concerning an unambiguous definition of the phenotype of CPC types. There is a need to define and validate the methods for the generation of quality CPC populations used in cell therapy applications. Considering the critical roles of cardiac cell progenitors in cellular therapy, we speculate that long term culture might modulate the immunophenotypes of CPCs. Hence, a strategy to validate the isolation and cell culture expansion of cardiac cell populations was devised. Isolation of three subpopulations of human CPCs was done from a single tissue sample using explant, enzymatic isolation, and c-kit+ immunomagnetic sorting methods. The study assessed the effects of ex vivo expansion on proliferation, immunophenotypes, and differentiation of CPCs. Additionally, we report that an explant culture can take over 2 months to achieve similar cell yields, and cell sorting requires a much larger starting population to match this expansion time frame. In comparison, an enzymatic method is expected to yield equivalent quantities of CPCs in 2-3 weeks, notably at a significantly lower cost, which may intensify their use in therapeutic approaches. We determined that ex vivo expansion caused changes in cellular characteristics, and hence propose validated molecular signatures should be established to evaluate the impact of ex vivo expansion for a safe cell therapy product.
Collapse
Affiliation(s)
- Suneel Rallapalli
- Biological Material Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai, India
| | | | - Purna S Korrapati
- Biological Material Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai, India
| |
Collapse
|
2
|
Dergilev KV, Tsokolayeva ZI, Beloglazova IB, Ratner EI, Parfyonova EV. Epicardial Transplantation of Cardiac Progenitor Cells Based Cells Sheets is More Promising Method for Stimulation of Myocardial Regeneration, Than Conventional Cell Injections. ACTA ACUST UNITED AC 2019; 59:53-60. [DOI: 10.18087/cardio.2019.5.2597] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2019] [Accepted: 05/25/2019] [Indexed: 11/18/2022]
Abstract
Today, transplantation of stem / progenitor cells is a promising approach for the treatment of heart diseases. The therapeutic potential of transplanted cells directly depends on the method of delivery to the myocardium, which determines their regenerative properties. It is important for the development of effective methods of cell therapy. In this paper, we performed a comparative study of efficacy of cardiac progenitor cell (CPC) transplantation by intramyocardial needle injections and by tissue engineering constructs (TEC) – “cell sheets” consisting of cells and their extracellular matrix. It has been shown, that transplantation of TEC in comparison with the intramyocardial delivery provides more extensive distribution and retains more proliferating cellular elements in the damaged myocardium, attenuates the negative cardiac remodeling of the left ventricle and promotes its vascularization.
Collapse
Affiliation(s)
| | | | | | | | - E. V. Parfyonova
- National Medical Research Center for Cardiology;
Lomonosov Moscow State University
| |
Collapse
|
3
|
Dergilev K, Tsokolaeva Z, Makarevich P, Beloglazova I, Zubkova E, Boldyreva M, Ratner E, Dyikanov D, Menshikov M, Ovchinnikov A, Ageev F, Parfyonova Y. C-Kit Cardiac Progenitor Cell Based Cell Sheet Improves Vascularization and Attenuates Cardiac Remodeling following Myocardial Infarction in Rats. BIOMED RESEARCH INTERNATIONAL 2018; 2018:3536854. [PMID: 30046593 PMCID: PMC6036839 DOI: 10.1155/2018/3536854] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 04/03/2018] [Accepted: 04/10/2018] [Indexed: 01/16/2023]
Abstract
The adult heart contains small populations of multipotent cardiac progenitor cells (CPC) that present a convenient and efficient resource for treatment of myocardial infarction. Several clinical studies of direct CPC delivery by injection have already been performed but showed low engraftment rate that limited beneficial effects of procedure. «Cell sheet» technology has been developed to facilitate longer retention of grafted cells and show new directions for cell-based therapy using this strategy. In this study we hypothesized that СPC-based cell sheet transplantation could improve regeneration after myocardial infarction. We demonstrated that c-kit+ CPC were able to form cell sheets on temperature-responsive surfaces. Cell sheet represented a well-organized structure, in which CPC survived, retained ability to proliferate, expressed progenitor cell marker Gata-4 formed connexin-43+ gap junctions, and were surrounded by significant amount of extracellular matrix proteins. Transplantation of cell sheets after myocardial infarction resulted in CPC engraftment as well as their proliferation, migration, and differentiation; cell sheets also stimulated neovascularization and cardiomyocyte proliferation in underlining myocardium and ameliorated left ventricular remodeling. Obtained data strongly supported potential use of CPC sheet transplantation for repair of damaged heart.
Collapse
Affiliation(s)
- K. Dergilev
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
| | - Z. Tsokolaeva
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
| | - P. Makarevich
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
- Laboratory of Gene and Cell Therapy, Institute of Regenerative Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - I. Beloglazova
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
- Laboratory of Gene and Cell Technology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - E. Zubkova
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
- Laboratory of Gene and Cell Technology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - M. Boldyreva
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
- Laboratory of Gene and Cell Technology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - E. Ratner
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
| | - D. Dyikanov
- Laboratory of Gene and Cell Technology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - M. Menshikov
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
| | - A. Ovchinnikov
- Consultative and Diagnostic Department, National Medical Research Center of Cardiology, Moscow, Russia
| | - F. Ageev
- Consultative and Diagnostic Department, National Medical Research Center of Cardiology, Moscow, Russia
| | - Ye. Parfyonova
- Laboratory of Angiogenesis, National Medical Research Center of Cardiology, Moscow, Russia
- Laboratory of Gene and Cell Technology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
4
|
Dergilev KV, Makarevich PI, Tsokolaeva ZI, Boldyreva MA, Beloglazova IB, Zubkova ES, Menshikov MY, Parfyonova YV. Comparison of cardiac stem cell sheets detached by Versene solution and from thermoresponsive dishes reveals similar properties of constructs. Tissue Cell 2016; 49:64-71. [PMID: 28041835 DOI: 10.1016/j.tice.2016.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 11/13/2016] [Accepted: 12/03/2016] [Indexed: 01/04/2023]
Abstract
Cell sheets (CS) from c-kit+ cardiac stem cell (CSC) hold a potential for application in regenerative medicine. However, manufacture of CS may require thermoresponsive dishes, which increases cost and puts one in dependence on specific materials. Alternative approaches were established recently and we conducted a short study to compare approaches for detachment of CS from c-kit+ CSC. Our in-house developed method using chelation by Versene solution was compared to UpCell™ thermoresponsive plates in terms of CSC proliferation, viability, gap junction formation and engraftment in a model of myocardial infarction. Use of Versene solution instead of thermoresponsive dishes resulted in comparable CS thickness (approximately 100mcm), cell proliferation rate and no signs of apoptosis detected in both types of constructs. However, we observed a minor reduction of gap junction count in Versene-treated CS. At day 30 after delivery to infarcted myocardium both types of CS retained at the site of transplantation and contained comparable amounts of proliferating cells indicating engraftment. Thus, we may conclude that detachment of CS from c-kit+ CSC using Versene solution followed by mechanical treatment is an alternative to thermoresponsive plates allowing use of routinely available materials to generate constructs for cardiac repair.
Collapse
Affiliation(s)
- Konstantin V Dergilev
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Pavel I Makarevich
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation; Lomonosov Moscow State University, Medical Research and Education Centre, Institute of Regenerative Medicine, Laboratory of gene and cell therapy, 119192, Moscow, Russian Federation.
| | - Zoya I Tsokolaeva
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Maria A Boldyreva
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Irina B Beloglazova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Ekaterina S Zubkova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Mikhail Yu Menshikov
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Yelena V Parfyonova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation; Lomonosov Moscow State University, Faculty of Medicine, Laboratory of gene and cell technologies, 119192, Moscow, Russian Federation
| |
Collapse
|